Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine *
暂无分享,去创建一个
G. Mufti | P. Fenaux | E. Hellström-Lindberg | S. Gore | V. Santini | J. Seymour | A. List | L. Silverman | J. Backstrom | C. L. Beach
[1] J. Hainsworth,et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Garcia-Manero. Improving survival in myelodysplastic syndromes. , 2009, The Lancet. Oncology.
[3] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[4] S. Gore,et al. The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update , 2008, Ecancermedicalscience.
[5] G. Mufti,et al. The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) , 2008 .
[6] H. Kantarjian,et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. , 2008, Journal of the National Cancer Institute.
[7] G. Mufti,et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission , 2008 .
[8] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Mufti,et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.
[10] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Holland,et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Cazzola,et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. , 2002, Haematologica.
[13] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.